Between the medical academic community crying foul over the med-tech startup’s lack of transparency and the SEC’s concerns about whether Theranos’ leadership misled investors, a more fundamental problem with the blood testing company has been overlooked. At least until now. Katherine Hobson at fivethirtyeight.com notes that there’s a flaw at the very core of the business, and it’s got nothing to do with the technology or claims made to investors. It’s that more sensitive tests and…
Comments closedCategory: Overdiagnosis
After writing a piece on concerns about blood-testing disruptor Theranos, I had the pleasure of being on the business end of Mark Cuban’s fury. And for that, I am truly thankful. Here’s the gist. Theranos aims to make blood testing a lot less expensive and a lot easier. One or two drops of blood are good for dozens of tests. Part of their vision is to enable healthy people to undergo more frequent testing and in doing so, more…
Comments closed